Table 2 Summary of treatment-emergent adverse events

From: Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

 

Maximum grade, n (%)

Grade 1

Grade 2

Grade 3

Grade 4

Thrombocytopeniaa

4 (11)

6 (17)

9 (26)

3 (9)

Blurred vision

2 (6)

15 (43)

1 (3)

0

Cough

11 (31)

3 (9)

0

0

Increased aspartate aminotransferase

8 (23)

3 (9)

2 (6)

0

Dry eye

6 (17)

6 (17)

1 (3)

0

Nausea

9 (26)

2 (6)

0

0

Anaemia

0

4 (11)

6 (17)

0

Diarrhoea

6 (17)

2 (6)

2 (6)

2 (6)

Photophobia

7 (20)

3 (9)

0

0

Pyrexia

6 (17)

4 (11)

0

0

Chills

7 (20)

2 (6)

0

0

Fatigue

2 (6)

6 (17)

0

0

Upper respiratory tract infection

5 (14)

3 (9)

0

0

Increased alanine aminotransferase

5 (14)

2 (6)

0

0

Back pain

3 (9)

2 (6)

2 (6)

0

Constipation

5 (14)

1 (3)

1 (3)

0

Increased γ-glutamyl transferase

2 (6)

3 (9)

2 (6)

0

Arthralgia

2 (6)

3 (9)

1 (3)

0

Increased blood alkaline phosphatase

6 (17)

0

0

0

Dyspnoea

4 (11)

1 (3)

1 (3)

0

Contusion

5 (14)

0

0

0

Decreased appetite

3 (9)

2 (6)

0

0

Headache

4 (11)

1 (3)

0

0

Sinusitis

0

5 (14)

0

0

Eye pain

3 (9)

0

1 (3)

0

Hypokalaemia

1 (3)

0

3 (9)

0

Infusion-related reaction

1 (3)

2 (6)

1 (3)

0

Lung infection

0

1 (3)

3 (9)

0

Pneumonia

0

1 (3)

3 (9)

0

Urinary tract infection

0

3 (9)

1 (3)

0

Hypertension

1 (3)

1 (3)

1 (3)

0

Keratitis

0

1 (3)

2 (6)

0

Decreased neutrophil count

0

0

3 (9)

0

Haematuria

0

1 (3)

1 (3)

0

Neutropenia

0

0

1 (3)

1 (3)

Rib fracture

1 (3)

0

1 (3)

0

Toothache

0

1 (3)

1 (3)

0

Appendicitis

0

0

1 (3)

0

Bacteraemia

0

0

0

1 (3)

Increased blood lactate dehydrogenase

0

0

1 (3)

0

Cataract

0

0

1 (3)

0

Cholecystitis acute

0

0

0

1 (3)

Cholecystitis infective

0

0

0

1 (3)

Deep vein thrombosis

0

0

1 (3)

0

Encephalopathy

0

0

1 (3)

0

Fall

0

0

1 (3)

0

Febrile neutropenia

0

0

1 (3)

0

Gastroenteritis

0

0

1 (3)

0

Humerus fracture

0

0

1 (3)

0

Lower respiratory tract infection

0

0

1 (3)

0

Pericardial effusion

0

0

0

1 (3)

Pneumonia haemophilus

0

0

1 (3)

0

Respiratory tract infection

0

0

1 (3)

0

Retinal detachment

0

0

1 (3)

0

Salmonellosis

0

0

1 (3)

0

Syncope

0

0

1 (3)

0

Abnormal visual acuity tests

0

0

1 (3)

0

  1. All adverse events of grades 3 and 4 are shown, and adverse events of grades 1 and 2 that occurred in 10% or more of patients (n = 35). No grade 5 events occurred
  2. aGrouped term includes thrombocytopenia and decrease in platelet count